IRADIMED CORP (IRMD) Stock Fundamental Analysis
NASDAQ:IRMD - Nasdaq - US46266A1097 - Common Stock - Currency: USD
Taking everything into account, IRMD scores 7 out of 10 in our fundamental rating. IRMD was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD has a correct valuation and a medium growth rate. These ratings would make IRMD suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
In the past year IRMD had a positive cash flow from operations.
Each year in the past 5 years IRMD has been profitable.
IRMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IRMD has a Return On Assets of 19.56%. This is amongst the best in the industry. IRMD outperforms 97.88% of its industry peers.
IRMD has a Return On Equity of 22.15%. This is amongst the best in the industry. IRMD outperforms 94.71% of its industry peers.
IRMD has a Return On Invested Capital of 19.36%. This is amongst the best in the industry. IRMD outperforms 98.41% of its industry peers.
IRMD had an Average Return On Invested Capital over the past 3 years of 18.78%. This is significantly above the industry average of 7.71%.
The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.36%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.56% | ||
| ROE | 22.15% | ||
| ROIC | 19.36% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.26%, IRMD belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
IRMD has a Operating Margin of 29.99%. This is amongst the best in the industry. IRMD outperforms 98.41% of its industry peers.
IRMD's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 76.94%, IRMD belongs to the best of the industry, outperforming 89.95% of the companies in the same industry.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.99% | ||
| PM (TTM) | 26.26% | ||
| GM | 76.94% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
Compared to 1 year ago, IRMD has more shares outstanding
IRMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IRMD has an Altman-Z score of 37.79. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
IRMD has a better Altman-Z score (37.79) than 98.94% of its industry peers.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 37.79 |
ROIC/WACC2.16
WACC8.97%
2.3 Liquidity
IRMD has a Current Ratio of 8.84. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 8.84, IRMD belongs to the best of the industry, outperforming 89.95% of the companies in the same industry.
A Quick Ratio of 7.62 indicates that IRMD has no problem at all paying its short term obligations.
IRMD's Quick ratio of 7.62 is amongst the best of the industry. IRMD outperforms 89.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.84 | ||
| Quick Ratio | 7.62 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.04%, which is quite good.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
IRMD shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.71%.
The Revenue has been growing by 13.71% on average over the past years. This is quite good.
EPS 1Y (TTM)11.04%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.71%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%10.86%
3.2 Future
The Earnings Per Share is expected to grow by 11.61% on average over the next years. This is quite good.
The Revenue is expected to grow by 13.15% on average over the next years. This is quite good.
EPS Next Y8.18%
EPS Next 2Y11.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.74%
Revenue Next 2Y13.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
IRMD is valuated quite expensively with a Price/Earnings ratio of 29.78.
Compared to the rest of the industry, the Price/Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 73.02% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of IRMD to the average of the S&P500 Index (28.10), we can say IRMD is valued inline with the index average.
With a Price/Forward Earnings ratio of 24.77, IRMD is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 75.13% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (20.74), we can say IRMD is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.78 | ||
| Fwd PE | 24.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 69.84% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 76.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.54 | ||
| EV/EBITDA | 26.91 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)3.64
PEG (5Y)2.14
EPS Next 2Y11.61%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.16%, IRMD has a reasonable but not impressive dividend return.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.86. IRMD pays more dividend than 94.71% of the companies in the same industry.
With a Dividend Yield of 1.16, IRMD pays less dividend than the S&P500 average, which is at 2.43.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
5.2 History
IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
71.11% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP71.11%
EPS Next 2Y11.61%
EPS Next 3YN/A
NASDAQ:IRMD (5/6/2025, 3:13:51 PM)
50.92
-1.38 (-2.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners58.66%
Inst Owner Change0.31%
Ins Owners37.05%
Ins Owner Change1%
Market Cap647.70M
Analysts82.5
Price Target72.42 (42.22%)
Short Float %2.58%
Short Ratio5.5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP71.11%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.77%
Min EPS beat(2)-1.96%
Max EPS beat(2)9.5%
EPS beat(4)3
Avg EPS beat(4)6.43%
Min EPS beat(4)-1.96%
Max EPS beat(4)12.81%
EPS beat(8)6
Avg EPS beat(8)6.97%
EPS beat(12)10
Avg EPS beat(12)7.51%
EPS beat(16)14
Avg EPS beat(16)15.55%
Revenue beat(2)0
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.71%
Revenue beat(4)1
Avg Revenue beat(4)-0.28%
Min Revenue beat(4)-0.72%
Max Revenue beat(4)0.72%
Revenue beat(8)4
Avg Revenue beat(8)0.18%
Revenue beat(12)4
Avg Revenue beat(12)-0.25%
Revenue beat(16)8
Avg Revenue beat(16)1.2%
PT rev (1m)0%
PT rev (3m)9.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.78 | ||
| Fwd PE | 24.77 | ||
| P/S | 8.84 | ||
| P/FCF | 38.54 | ||
| P/OCF | 25.28 | ||
| P/B | 7.46 | ||
| P/tB | 7.74 | ||
| EV/EBITDA | 26.91 |
EPS(TTM)1.71
EY3.36%
EPS(NY)2.06
Fwd EY4.04%
FCF(TTM)1.32
FCFY2.59%
OCF(TTM)2.01
OCFY3.96%
SpS5.76
BVpS6.83
TBVpS6.58
PEG (NY)3.64
PEG (5Y)2.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.56% | ||
| ROE | 22.15% | ||
| ROCE | 24.46% | ||
| ROIC | 19.36% | ||
| ROICexc | 46.27% | ||
| ROICexgc | 50.43% | ||
| OM | 29.99% | ||
| PM (TTM) | 26.26% | ||
| GM | 76.94% | ||
| FCFM | 22.95% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexcg growth 3Y-6.9%
ROICexcg growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1078.24% | ||
| Cap/Sales | 12.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.47% | ||
| Profit Quality | 87.39% | ||
| Current Ratio | 8.84 | ||
| Quick Ratio | 7.62 | ||
| Altman-Z | 37.79 |
F-Score8
WACC8.97%
ROIC/WACC2.16
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.04%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
EPS Next Y8.18%
EPS Next 2Y11.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.71%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%10.86%
Revenue Next Year8.74%
Revenue Next 2Y13.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.61%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y207.96%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y90.3%
OCF growth 3Y31.53%
OCF growth 5Y20.16%